Recombinant Anti-ROS1 antibody [EPMGHR2] (ab189925)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPMGHR2] to ROS1
- Suitable for: IHC-P
- Reacts with: Human
Overview
-
Product name
Anti-ROS1 antibody [EPMGHR2]
See all ROS1 primary antibodies -
Description
Rabbit monoclonal [EPMGHR2] to ROS1 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary.
Database link: P08922 -
Positive control
- IHC-P: Human lung carcinoma tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPMGHR2 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab189925 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | 1/300. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. For unpurified use at 1/100-1/250. See IHC antigen retrieval protocols. |
Target
-
Function
This is probably a cell growth or differentiation factor receptor with a tyrosine-protein kinase activity. -
Tissue specificity
Expressed in brain. Expression is increased in primary gliomas. -
Involvement in disease
Note=A chromosomal aberration involving ROS1 is found in a glioblastoma multiforme sample. An intra-chromosomal deletion del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric protein which has a constitutive receptor tyrosine kinase activity. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Contains 9 fibronectin type-III domains.
Contains 1 protein kinase domain. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 6098 Human
- Omim: 165020 Human
- SwissProt: P08922 Human
- Unigene: 1041 Human
-
Alternative names
- c ros 1 antibody
- c ros antibody
- c ros oncogene 1 receptor tyrosine kinase antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ROS1 antibody [EPMGHR2] (ab189925)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lung carcinoma tissue sections labeling ROS1 with Purified ab189925 at 1:300 dilution (5.23 μg/ml). Heat mediated antigen retrieval was performed using EDTA Buffer, pH9.0. Tissue was counterstained with hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ROS1 antibody [EPMGHR2] (ab189925)
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labeling ROS1 with unpurified ab189925 at 1/250 dilution followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with hematoxylin. (Inset: negative control).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Datasheets and documents
Certificate of Compliance
References (1)
ab189925 has been referenced in 1 publication.
- Rossi G et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl) 8:45-55 (2017). IHC . PubMed: 28740441